Navigation Links
Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes
Date:3/4/2009

The 2009 Walk to Cure Diabetes will be held Saturday, October 17 at

Centennial Olympic Park

ATLANTA, March 4 /PRNewswire/ -- The Georgia Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced that Blue Cross and Blue Shield of Georgia (BCBSGa) President, Monye Connolly, will serve as the Corporate Chair for its annual, and largest, fundraising event, Walk to Cure Diabetes. The event is scheduled in Atlanta at Centennial Olympic Park on Saturday, Oct. 17, 2009.

Last year's walk raised more than $1.5 million to fund research to help find a cure for diabetes.

"The Juvenile Diabetes Research Foundation is firm in its commitment to finding a cure for diabetes and its complications through the support of research. BCBSGa truly believes in JDRF and its mission, which supports our mission of improving the lives of the people we serve and the health of our communities," said Connolly.

"We look forward to working with Monye Connolly in the months to come to make the 2009 Walk our best one ever. As someone with type 1 diabetes myself, it is very gratifying to have the support of such a large, successful company in our relentless goal to find a cure for diabetes and its complications," said Kris Bagwell, JDRF Georgia Board President

As many as 3 million people in the U.S. are now living with type 1 diabetes. Each year more than 15,000 children are diagnosed with diabetes - that's 40 children per day. More than 85 percent of JDRF's expenditures directly support research and research-related education.

Corporate sponsorships, corporate Walk Teams and Family Walk Teams will be the key to the success of the Walk to Cure Diabetes. For more information about JDRF, the critical research they fund and how you can help, call 404-420-5990, or visit www.jdrf.org.

About JDRF:

JDRF was founded in 1970 by the parents of children with type-1 diabetes - a disease that strikes children, adolescents and adults suddenly, making them insulin dependent for life, which carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.3 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. To register now and participate, sponsor an event, build a walk team, or for more information, please visit www.jdrf.org, or call 404-420-5990.

About Blue Cross Blue Shield of Georgia:

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association(R) . The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Blue Cross and Blue Shield of Georgia is available at www.bcbsga.com.


'/>"/>
SOURCE Juvenile Diabetes Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvanians May Donate Part of Tax Refund to Support Juvenile Diabetes Research
2. Etanercept, Methotrexate Safe for Juvenile RA
3. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Drug May Ease Symptoms of Juvenile Arthritis
6. Pediatric researchers find possible master switch gene in juvenile arthritis
7. Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis
8. Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis
9. Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball
10. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
11. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of ... the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” ... offers a 70% tax credit to individuals and corporations which donate directly to a ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only ... majority of skin cancer deaths. More than 10,000 people are expected to die of melanoma ... 62, it is the one of the most commonly diagnosed cancers in young women. A ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
Breaking Medicine Technology: